Precision BioSciences Files Fourth Patent Infringement Lawsuit Against Cellectis Related to Engineered Meganucleases

    RESEARCH TRIANGLE PARK, NC, February 28, 2012 /24-7PressRelease/ -- Precision BioSciences, Inc., a leader in the field of genome engineering, today announced that it has filed a fourth patent infringement lawsuit against Cellectis SA and a number of its affiliates in the U.S. District Court for the Eastern District of North Carolina. The lawsuit seeks a ruling that Cellectis' manufacture, use, sale, and importation of certain engineered meganucleases infringe U.S. Patent No. 8,124,369 which relates to Precision BioSciences' ground-breaking Directed Nuclease Editor genome engineering technology. The lawsuits request monetary damages as well as a permanent injunction preventing Cellectis from making, using, selling, offering for sale, or importing infringing engineered meganucleases in the United States. Precision BioSciences previously announced that it had filed suit against Cellectis for alleged infringement of U.S. Patent Nos. 8,021,867, 8,119,381 and 8,119,361.

About Precision BioSciences
Precision BioSciences' mission is to continually provide, improve, and enable the world's most powerful genome engineering technology. Precision's proprietary Directed Nuclease EditorTM (DNE) technology enables the production of genome editing enzymes that can insert, remove, modify, and regulate essentially any gene in mammalian or plant cells.

Precision BioSciences' vision is to be the conduit through which the world's greatest genome engineering challenges are solved. Precision has successfully utilized its DNE technology to create innovative products in partnerships with many of the world's largest biopharmaceutical, agbiotech, and animal research firms. Internally, Precision is developing applications of DNE in biological production and human therapeutics. For additional information, please visit www.precisionbiosciences.com.

Contact:
Precision BioSciences: Chelsea Lynam, phone: +1 919 314-5512
E-mail: [email protected]

# # #